NEW YORK (GenomeWeb) – Sequenom said today that its second-half 2015 revenues will be lower than previously anticipated and has accordingly dropped its full-year revenue guidance to a range of 15 percent to 23 percent lower than its previous estimate of $150 million to $170 million.

The firm expects second-half 2015 revenues to be in the range of $57 million to $61 million and full-year revenues to be between $127 million and $131 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.